Ketogenic Diet Shows Promise in Psychotic Disorders Trial
Recent clinical trials indicate that a ketogenic diet may serve as an effective adjunctive tool for patients with serious mental illness by addressing metabolic markers.
An emerging body of research is challenging the traditional focus of psychiatric treatment by demonstrating that metabolic interventions may improve outcomes for patients with serious mental illness. Recent clinical trials from the University of California, San Francisco (UCSF) and Stanford Medicine indicate that a ketogenic diet—a high-fat, low-carbohydrate regimen—may serve as an effective adjunctive tool for individuals diagnosed with schizophrenia and bipolar disorder.
For decades, standard antipsychotic medications have served as the primary defense against psychotic symptoms. While these drugs are effective for many, they frequently cause severe metabolic side effects, including insulin resistance, weight gain, and obesity. According to researchers, these complications can be so distressing that some patients discontinue their prescribed treatments. Findings published in the Schizophrenia Bulletin and Psychiatry Research suggest that metabolic therapy could address these physiological concerns while simultaneously alleviating psychiatric and cognitive symptoms.
Media additions
Clinical Evidence and Metabolic Impact
A first-of-its-kind randomized controlled trial (RCT) conducted by researchers at UCSF, funded in part by the National Institute of Mental Health (NIMH), examined the impact of a ketogenic diet on participants with schizophrenia-spectrum or bipolar-1 disorders. Of the 58 participants enrolled, 47 completed an initial comparison between a one-month ketogenic diet and a diet-as-usual control group. The study demonstrated high feasibility, with 83% of daily-tested participants maintaining ketosis during the initial phase. Participants who maintained higher ketone levels experienced significant reductions in blood glucose and depression symptoms, even when accounting for weight loss. This suggests that the physiological state of ketosis itself may play a primary role in improving mental well-being. A subsequent four-month single-arm extension, involving 25 participants, showed sustained improvements in metabolic markers, schizophrenia symptoms, and cognitive performance.
Separately, Stanford Medicine published findings from a pilot trial that followed 21 adult participants over four months. By the end of this study, no participants met the criteria for metabolic syndrome, a shift from the 29% who met those criteria at the trial’s outset. Participants also showed a 31% average improvement in psychiatrist-rated mental illness scales. Research teams from the University of Michigan, UCSF, and Duke University contributed to this study, which was supported by the Baszucki Group Research Fund, the Kuen Lau Fund, and the Obesity Treatment Foundation.
Understanding the Mechanism
The core hypothesis driving this research is that psychiatric disorders like schizophrenia may stem from metabolic deficits in the brain. The brain is an energy-intensive organ, and researchers believe that in patients with severe mental illness, the brain may suffer from energy conversion dysfunction. This approach, coined "metabolic psychiatry" by Shebani Sethi of Stanford Medicine, views mental health through the lens of energy conversion.
Perspectives and Future Research
While the initial results are promising, experts emphasize that these studies represent a preliminary step. Judith M. Ford, Professor of Psychiatry at UCSF and the Weill Institute for Neurosciences, noted that the current findings underscore the need for larger, longer, and fully controlled trials to establish the efficacy and safety of the diet at scale. Similar sentiments were shared by Shebani Sethi, the founding director of the Stanford Metabolic Psychiatry Clinic, who views the diet as a valuable potential adjunctive treatment.
Philanthropic interest has mobilized around these findings. Jan Ellison Baszucki, co-founder of the Baszucki Group, stated that the pilot studies provide a foundation for further investment in metabolic approaches to psychiatry. The Baszucki Group has committed funding toward larger randomized controlled trials at institutions such as McLean Hospital and the University of Pittsburgh. As the scientific community continues to move beyond traditional neurotransmission models, researchers hope that validating these metabolic interventions will lead to more integrative and personalized treatment strategies for patients who have found little relief in conventional pharmaceuticals.
